Marksans Pharma Shares Jump 1.3% on UK MHRA Nod for Breast Cancer Drug

Pharma Ltd shares rose 1.26% to ₹189.10 in early trade on November 6 after its UK arm Relonchem secured marketing authorization from the UK MHRA for Exemestane 25mg film-coated tablets, a key generic treatment for breast cancer. This marks the second MHRA approval in a month for Relonchem, following Clonidine tablets clearance in October. The stock, which closed at ₹186.75 yesterday, now trades 47% below its 52-week high of ₹358.50 (Dec 5, 2024) but 17% above its year-low of ₹162.05. Market cap stands at ₹8,569 crore. The board will meet on November 13 to approve Q2 FY26 results